DOS新辅助化疗对局部晚期胃上部癌的临床价值

Clinical Value of DOS Neoadjuvant Chemotherapy for Locally Advanced Upper Gastric Carcinoma

目的探讨局部晚期胃上部癌采用多西他赛、奥沙利铂联合替吉奥(DOS)新辅助化疗的临床效果。方法随机抽取2017年1月—2018年1月本院行DOS新辅助化疗的局部晚期胃上部癌患者24例为研究组。以同样方法选择同期行奥沙利铂、替吉奥(SOX)辅助化疗的局部晚期胃上部癌患者24例为对照组。对比两组治疗效果及安全性。结果研究组、对照组近期总有效率疗效分别为91.67%、83.33%(P> 0.05);化疗期间,研究组轻度骨髓抑制、消化道反应发生率低于对照组(P <0.05),但两组末梢神经炎发生率对比差异无统计学意义(P> 0.05);两组均未出现严重骨髓抑制、肝肾功能障碍等不良反应。结论局部晚期胃上部癌患者实施DOS新辅助化疗的效果显著。

Objective To explore the clinical effect of docetaxel and oxaliplatin combined with tegafur neoadjuvant chemotherapy(DOS)in local advanced gastric upper carcinoma.Methods From January 2017 to January 2018,24 patients with locally advanced supergastric cancer who underwent DOS neoadjuvant chemotherapy in our hospital were randomly selected as the research group.Similarly,24 patients with locally advanced supergastric cancer who underwent concurrent oxaliplatin and tegafur(SOX)adjuvant chemotherapy were selected as the control group.The efficacy and safety of the two groups were compared.Results The short-term total effective rate of the study group and the control group was 91.67%and 83.33%respectively(P>0.05).During chemotherapy,the incidence of mild bone marrow suppression and digestive tract reaction in the study group was lower than that in the control group(P<0.05).However,there was no statistically significant difference in the incidence of peripheral neuritis between the two groups(P>0.05).There were no serious adverse reactions such as bone marrow suppression,liver and kidney dysfunction in both groups.Conclusion The effect of DOS neoadjuvant chemotherapy on patients with locally advanced upper gastric cancer is significant.